bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
210 hedge funds and large institutions have $4.24B invested in bluebird bio in 2017 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 56 increasing their positions, 80 reducing their positions, and 18 closing their positions.
106% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 18
71% more call options, than puts
Call options by funds: $60M | Put options by funds: $35.1M
47% more capital invested
Capital invested by funds: $2.88B → $4.24B (+$1.36B)
6% more funds holding
Funds holding: 199 → 210 (+11)
0.06% less ownership
Funds ownership: 8.87% → 8.81% (-0.06%)
30% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 80
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$250M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$37.9M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$21.8M |
| 4 |
PC
PointState Capital
New York
|
+$13.3M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.6M |
| 2 |
DM
Deerfield Management
New York
|
-$15.4M |
| 3 |
AG
Artal Group
Luxembourg
|
-$13.6M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$11.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$10.1M |
BLUE Hedge Fund Activity: Q1 2017 in Review
210 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2017, worth a combined $4.24B — up 47% from $2.88B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new BLUE positions and 18 closed out — a net gain of 19 holders — while 56 added to existing stakes and 80 trimmed.
The largest buyer was BlackRock, adding an estimated $250M. The largest seller was T. Rowe Price Associates, cutting an estimated $16.6M.
- 210 institutional investors held bluebird bio (BLUE) as of Q1 2017, up from 199 in Q4 2016.
- Funds reported $4.24B of bluebird bio stock for Q1 2017, up 47% quarter-over-quarter.
- 37 funds opened new bluebird bio positions in Q1 2017 and 18 closed out, a net change of +19 holders.
- The largest bluebird bio buyer in Q1 2017 was BlackRock, an estimated $250M added.
- The largest bluebird bio seller in Q1 2017 was T. Rowe Price Associates, an estimated $16.6M sold.
Based on aggregated 13F filings for Q1 2017.